Direkt zum Inhalt
Merck
  • E-cadherin gene variants in gastric cancer families whose probands are diagnosed with diffuse gastric cancer.

E-cadherin gene variants in gastric cancer families whose probands are diagnosed with diffuse gastric cancer.

International journal of cancer (2002-09-07)
Tomonori Yabuta, Kazuya Shinmura, Masachika Tani, Satoru Yamaguchi, Kimio Yoshimura, Hitoshi Katai, Takashi Nakajima, Erito Mochiki, Toshimasa Tsujinaka, Motohisa Takami, Kazuo Hirose, Akio Yamaguchi, Seiichi Takenoshita, Jun Yokota
ZUSAMMENFASSUNG

To identify germline E-cadherin mutations responsible for the predisposition to diffuse gastric cancer (DGC) among the Japanese, we screened 17 patients with familial aggregation of gastric cancer by sequencing analysis. All the patients were diagnosed with DGC and had at least 1 sibling with gastric cancer. Two novel E-cadherin gene variants were detected. One was detected in 1 patient only and associated with an amino acid substitution (Val/Met) at codon 832 in the region essential for binding to beta-catenin. The M832 variant was detected not only in the proband but also in 2 other gastric cancer patients in the family. Immunohistochemical analysis of gastric cancer tissue from the proband revealed that E-cadherin expression was markedly reduced and beta-catenin expression was also reduced in cancer cells. However, no significant difference in the activity of beta-catenin binding was detected between the M832 variant and V832 wild-type E-cadherin in immunofluorescence and immunoprecipitation/Western blot analyses. The other was detected in 5 patients and was located in the splice donor site (IVS1+6T/C); however, RT-PCR analysis indicated that the IVS+6C variant did not cause an aberrant splicing. Thus, the M832 variant could be a germline mutation causative of familial aggregation of DGC, although further functional studies are needed to understand the pathogenic significance of this variant.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Roche
7-Deaza-2′-desoxyguanosin 5′-triphosphat Lithiumsalz, 95% (7-Deaza-dGTP, HPLC), ≤4% (7-Deaza-dGDP, HPLC), solution, 10 mM